Bayer Schering job cuts on target

Williams, Dede
June 2007
ICIS Chemical Business;6/4/2007, Vol. 2 Issue 69, p11
Trade Publication
This article states that Bayer Schering Pharma has reached agreement with nearly two-thirds of the Berlin, Germany-based employees who will lose their jobs in the company's merger-related workforce reduction plan. The plan foresees the elimination of 6,100 group positions, including 1,500 in Germany. Speaking at the Bayer Group annual general meeting, managing board member Werner Baumann stressed that most of the reductions would be made through early retirement and severance pay packages.


Related Articles

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • Europe watch.  // ICIS Chemical Business Americas;3/26/2007, Vol. 271 Issue 12, p14 

    The article presents news briefs on chemical producer Bayer as of March 2007. The company reached an agreement with the works council at the Bayer Schering Pharma on an acceptable plan for implementing its job cuts after their merger. Bayer paid $1.2 billion as settlement for 3,152 out-of-court...

  • Job losses at Bayer Schering. Williams, Dede; Gibson, Jane // ICIS Chemical Business;2/26/2007, Vol. 2 Issue 55, p10 

    The article reports on the expected downsizing at the Berlin, Germany headquarters of Bayer Schering Pharma. Headcount reductions of 300 in marketing and distribution are already planned, council head Norbert Deutschmann told the German press. Schering employees expected that only 600 jobs would...

  • NICE recommends all patients admitted to hospital are risk assessed for VTE.  // Operating Theatre Journal;Feb2010, Issue 233, p3 

    The article announces the launching of Bayer Schering Pharma AG with its implementation toolkit for the prevention of Venous Thromboembolism (VTE) in Great Britain.

  • Healthcare: Ethical Bayer Australia.  // Media: Asia's Media & Marketing Newspaper;11/19/2009, p33 

    The article reports on the use of public relations (PR) by Bayer Schering Pharma AG (BSP) as the main marketing platform to launch its oral contraceptives in Australia in 2009.

  • BiTE Advances to Preclinical Studies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the plans of Micromet Inc. to advance its BiTE antibody MT112/BAY2010112 into formal preclinical development in collaboration with Bayer Schering Pharma AG.

  • New progestins eyed for contraception in U.S.  // Contraceptive Technology Update;Aug2009, Vol. 30 Issue 8, p89 

    The article reports on the clinical trials conducted by biopharmaceutical company Bayer Schering Pharma AG on the use of contraceptive progestins using ethinyl estradiol and gestodene among women in the U.S.

  • Bayer Schering Bites on BiTE Option for Micromet Antibody.  // BioWorld Today;12/2/2009, Vol. 20 Issue 231, p2 

    The article reprots that Micromet Inc. will be given 7.5 million U.S. dollars and future milestone payments following the decision of Bayer Schering Pharma AG to develop a preclinical BiTE antibody for cancer.

  • ExL Pharma's Leading European Digital Marketing & PR Conference to be Hosted @ Bayer Schering.  // Biomedical Market Newsletter;5/12/2011, p146 

    The article offers information on the Second Annual Digital Pharma Europe and European Public Relations & Communications Summit to be hosted by Bayer Schering Pharma AG on March 29 to 30, 2010 in Berlin, Germany.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics